Companies Cryptocurrencies
Orchard Therapeutics PLC
Orchard Therapeutics PLC
Exchange: NasdaqGS
IPO Date: 31/10/2018
CEO: Prof. Bobby Gaspar Ph.D., M.D.
Biotechnology Healthcare 🔗
  • ORTX
  • 0.4683
  • 58961312
    market cap
  • -0.00579998
If you bought

shares of Orchard Therapeutics PLC (ORTX) on
You would have made
Old Price $12 Current Price $12

Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company is engaged in manufacturing and commercialization of gene and cell therapies, position to provide transformative therapies to patients suffering from a range of rare diseases. The firm is focused on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders and hemoglobinopathies. Its portfolio includes Strimvelis, its commercial-stage gammaretroviral-based product for the treatment of ADA-SCID five lentiviral product candidates in clinical-stage development and several other product candidates in preclinical development. The company is developing OTL-101 as an autologous ex vivo lentiviral gene therapy to sustainably treat patients with adenosine deaminase severe combined immunodeficiency (ADA-SCID) through a single administration.

Address: 108 Cannon Street LONDON EC4N 6EU

Stay updated.